Pfizer’s presence at ASCO 2023
TALZENNA® + XTANDI® in patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).Find Out More
BRAFTOVI® + MEKTOVI® significantly improves objective response rates in metastatic non-small cell lung cancer (NSCLC).Find Out More
We are presenting updated data from our comprehensive MagnetisMM multiple myeloma clinical development program across 13 abstracts.Find Out More
Our presented data spans 15+ therapies across 10+ types of cancer, including six early pipeline medicines.Read Our Press Release
Our commitment to advancing scientific innovation will be displayed with 40+ accepted abstracts from our growing oncology portfolio.See Our Abstract List
Over the past decade, we’ve taken bold new approaches to translate scientific research into effective medicines for people living with cancer.Learn More
All Pfizer published press releases by date and/or category of news
03.16.2023 Medicines Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer 03.16.2023 Covid-19 Medicines FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for Pfizer’s PAXLOVID™ 03.14.2023 Vaccines Covid-19 Vaccines Pfizer and BioNTech Receive U.S. Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Booster in Children Under 5 Years
Media Asset Library
A collection of assets for use by media.
The latest news from Pfizer and its strategic partners
01.18.2022 Partnerships Sema4 to Acquire GeneDx, Strengthening its Market-Leading AI-Driven Genomic and Clinical Data Platform 01.11.2022 Partnerships Dren Bio Announces Research Collaboration and License Agreement with Pfizer to Discover and Advance Multiple Therapeutic Antibodies Using its Targeted Myeloid Engager and Phagocytosis Platform for the Treatment of Cancer
Pfizer Media Relations
We encourage everyone to view our press releases, press statements, and press kits to stay up to date on Pfizer news.
However, to ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may only respond to calls and emails from professional journalists.
United States, Canada and Latin America
Europe, the Middle East and Africa
What we need
To best help us help you, please be prepared to provide your name and email address, a summary of the article you're working on and your deadline.
Other Frequently Visited Links
For more, see these helpful and often used sections of Pfizer.com
Stay up to date on the latest news and alerts through the Pfizer Wire
Sign up to receive real-time updates on Pfizer’s news from the Pfizer Media Relations team delivered directly to your inbox.